Table 1.
Patient characteristics and clinical variables (N = 231).
| Variable | Study sample |
|---|---|
| Age at surgery, mean (SD) | 48.3 (14.5) |
| Female, n (%) | 97 (42.0) |
| KPS1 at admission, median (Q1, Q3) | 90 (80, 90) |
| WHO 2016 classification, n (%) | |
| Oligodendroglioma, WHO grade 2 | 36 (15.6) |
| Oligodendroglioma, WHO grade 3 | 33 (14.3) |
| Diffuse astrocytoma, IDH-mutant, WHO grade 2 | 36 (15.6) |
| Astrocytoma, IDH-mutant, WHO grade 3 | 39 (16.9) |
| Diffuse astrocytic glioma, IDH-wildtype, WHO grade 2 | 47 (20.3) |
| Diffuse astrocytic glioma, IDH-wildtype, WHO grade 3 | 40 (17.3) |
| Seizure, n (%) | 157 (68.0) |
| Neurological deficit at admission, n (%) | |
| Motor | 28 (12.1) |
| Cognitive | 39 (16.9) |
| Visual | 12 (5.2) |
| Language | 28 (12.1) |
| Any neurological deficit | 76 (32.9) |
| Type of neurosurgical intervention, n (%) | |
| Tumor resection | 184 (79.7) |
| Seizure2, n (%) | 8 (3.5) |
| New neurological deficit 3, n (%) | |
| Motor | 49 (21.2) |
| Cognitive | 22 (9.5) |
| Visual | 17 (7.4) |
| Language | 45 (19.5) |
| Any new neurological deficit | 89 (38.5) |
| Transient deficit | 40 (17.3) |
| Permanent deficit | 49 (21.2) |
| Deficits in more than one domain | 36 (15.6) |
1Karnofsky Performance Status Scale.
2New or worsened. Neither prophylactic or therapeutic use of anti-epileptic drugs were recorded for the study.
3New neurological deficits were defined as new or worsened from surgery to the 3-month follow-up.